Pharmacological obesity treatment with second-generation GLP1 agonists or double GLP1-GIP agonists has revolutionized obesity management in recent years, and related studies may provide interesting insight about therapeutic weight loss and body composition – notably independent of structured prevention strategies to minimize muscle loss (such as enhanced protein dietary intake or exercise training programmes), that were not included in the treatment protocols. The gene discussed is GIP; the disease is Obesity.